PMID- 22669131
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20220316
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 18
IP  - 12
DP  - 2012 Jun 15
TI  - Best practices in cancer nanotechnology: perspective from NCI nanotechnology 
      alliance.
PG  - 3229-41
LID - 10.1158/1078-0432.CCR-11-2938 [doi]
AB  - Historically, treatment of patients with cancer using chemotherapeutic agents has 
      been associated with debilitating and systemic toxicities, poor bioavailability, 
      and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on 
      the other hand, can specifically target cancer cells while avoiding their healthy 
      neighbors, avoid rapid clearance from the body, and be administered without toxic 
      solvents. They hold immense potential in addressing all of these issues, which 
      has hampered further development of chemotherapeutics. Furthermore, such drug 
      delivery systems will lead to cancer therapeutic modalities that are not only 
      less toxic to the patient but also significantly more efficacious. In addition to 
      established therapeutic modes of action, nanomaterials are opening up entirely 
      new modalities of cancer therapy, such as photodynamic and hyperthermia 
      treatments. Furthermore, nanoparticle carriers are also capable of addressing 
      several drug delivery problems that could not be effectively solved in the past 
      and include overcoming formulation issues, multidrug-resistance phenomenon, and 
      penetrating cellular barriers that may limit device accessibility to intended 
      targets, such as the blood-brain barrier. The challenges in optimizing design of 
      nanoparticles tailored to specific tumor indications still remain; however, it is 
      clear that nanoscale devices carry a significant promise toward new ways of 
      diagnosing and treating cancer. This review focuses on future prospects of using 
      nanotechnology in cancer applications and discusses practices and methodologies 
      used in the development and translation of nanotechnology-based therapeutics.
CI  - (c)2012 AACR.
FAU - Zamboni, William C
AU  - Zamboni WC
AD  - UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, 
      Carolina Center for Cancer Nanotechnology Excellence, UNC Institute for 
      Pharmacogenomics and Individualized Therapy, The University of North Carolina at 
      Chapel Hill, Chapel Hill, North Carolina, USA. zamboni@unc.edu
FAU - Torchilin, Vladimir
AU  - Torchilin V
FAU - Patri, Anil K
AU  - Patri AK
FAU - Hrkach, Jeff
AU  - Hrkach J
FAU - Stern, Stephen
AU  - Stern S
FAU - Lee, Robert
AU  - Lee R
FAU - Nel, Andre
AU  - Nel A
FAU - Panaro, Nicholas J
AU  - Panaro NJ
FAU - Grodzinski, Piotr
AU  - Grodzinski P
LA  - eng
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
GR  - P30 CA016086/CA/NCI NIH HHS/United States
GR  - U54 CA151652/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20120605
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/pharmacokinetics/*therapeutic use
MH  - Blood-Brain Barrier
MH  - Drug Delivery Systems/*methods
MH  - Drug Discovery
MH  - Humans
MH  - *Nanoparticles
MH  - Nanotechnology
MH  - National Cancer Institute (U.S.)
MH  - Neoplasms/*drug therapy/therapy
MH  - Tissue Distribution
MH  - United States
PMC - PMC3916007
MID - NIHMS371064
EDAT- 2012/06/07 06:00
MHDA- 2012/12/21 06:00
PMCR- 2014/02/06
CRDT- 2012/06/07 06:00
PHST- 2012/06/07 06:00 [entrez]
PHST- 2012/06/07 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
PHST- 2014/02/06 00:00 [pmc-release]
AID - 1078-0432.CCR-11-2938 [pii]
AID - 10.1158/1078-0432.CCR-11-2938 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2012 Jun 15;18(12):3229-41. doi: 10.1158/1078-0432.CCR-11-2938. 
      Epub 2012 Jun 5.